News | 28 June 2012
"We believe that no generics to OxyContin should be approved that are not formulated to be abuse-deterrent," says a spokesman for the company, whose OxyContin sales reached more than $2.8 billion last year. Enlarge Image. image. Close. image ...
Click on the link to read the full article at Wall Street Journal
(This link will open in a new window)